Immunitor unveils breakthrough immunotherapy to treat tuberculosis in...

Immunitor Inc., commercial-stage biotech company, is pleased to announce the publication of positive results from the randomized, placebo-controlled Phase III clinical trial for Tubivac (V7), the...(PRWeb January 31, 2020)Read the full story at https://www.prweb.com/releases/immunitor_unveils_breakthrough_immunotherapy_to_treat_tuberculosis_in_as_short_as_one_month/prweb16874150.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news